Thus, the potential GLP1-RA or SGLT2i treatment effect heterogeneity identified across groups of patients with and without established cardiovascular disease would not be deemed significant in the setting of adjusted p-values. This evidence concerns the gene GLP1R and cardiovascular disorder.